Oral administration of nimbolide, over 12 weeks shows reduction of prostate tumour size by up to 70 per cent and decrease in tumour metastasis by up to 50 per cent
A team of international researchers led by Associate Professor Gautam Sethi from the Department of Pharmacology at the Yong Loo Lin School of Medicine at the National University of Singapore (NUS) has found that nimbolide, a bioactive terpenoid compound derived from Azadirachta indica or more commonly known as the neem plant, could reduce the size of prostate tumour by up to 70 per cent and suppress its spread or metastasis by half.
Prostate cancer is one of the most commonly diagnosed cancers worldwide. However, currently available therapies for metastatic prostate cancer are only marginally effective. Hence, there is a need for more novel treatment alternatives and options.
“Although the diverse anti-cancer effects of nimbolide have been reported in different cancer types, its potential effects on prostate cancer initiation and progression have not been demonstrated in scientific studies. In this research, we have demonstrated that nimbolide can inhibit tumour cell viability – a cellular process that directly affects the ability of a cell to proliferate, grow, divide, or repair damaged cell components – and induce programmed cell death in prostate cancer cells,” said Assoc Prof Sethi.
Nimbolide: promising effects on prostate cancer
Cell invasion and migration are key steps during tumour metastasis. The NUS-led study revealed that nimbolide can significantly suppress cell invasion and migration of prostate cancer cells, suggesting its ability to reduce tumour metastasis.
The researchers observed that upon the 12 weeks of administering nimbolide, the size of prostate cancer tumour was reduced by as much as 70 per cent and its metastasis decreased by about 50 per cent, without exhibiting any significant adverse effects.
“This is possible because a direct target of nimbolide in prostate cancer is glutathione reductase, an enzyme which is responsible for maintaining the antioxidant system that regulates the STAT3 gene in the body. The activation of the STAT3 gene has been reported to contribute to prostate tumour growth and metastasis,” explained Assoc Prof Sethi. “We have found that nimbolide can substantially inhibit STAT3 activation and thereby abrogating the growth and metastasis of prostate tumour,” he added.
The findings of the study were published in the April 2016 issue of the scientific journal Antioxidants & Redox Signaling. This work was carried out in collaboration with Professor Goh Boon Cher of Cancer Science Institute of Singapore at NUS, Professor Hui Kam Man of National Cancer Centre Singapore and Professor Ahn Kwang Seok of Kyung Hee University.
Neem – The medicinal plant
The neem plant belongs to the mahogany tree family that is originally native to India and the Indian sub-continent, but is now also commonly found in Singapore. It has been part of traditional Asian medicine for centuries and is typically used in Indian Ayurvedic medicine. Today, neem leaves and bark have been incorporated into many personal care products such as soaps, toothpaste, skincare and even dietary supplements. Neem seedlings can also be obtained from the Indian flower shops at Campbell Lane and Buffalo Road areas within Serangoon Road in Singapore.
The team is looking to embark on a genome-wide screening or to perform a large-scale study of proteins to analyse the side-effects and determine other potential molecular targets of nimbolide. They are also keen to investigate the efficacy of combinatory regimen of nimbolide and approved drugs such as docetaxel and enzalutamide for future prostate cancer therapy.
The Latest on: Prostate cancer
via Google News
The Latest on: Prostate cancer
- Great Murray River Postie Bike Adventure fund prostate cancer clinical trial nurse on February 21, 2019 at 10:00 pm
It was an explosive start to the Great Murray River Postie Bike Adventure for one Albury team. Dennis France, David Pye, Guy Corbett and Ella Corbett encountered issues before they'd even arrived in B... […]
- Immunotherapy Combo Active in Metastatic Prostate Cancer on February 21, 2019 at 9:24 pm
SAN FRANCISCO — Immune checkpoint inhibitor monotherapy has so far had little success in the treatment of prostate cancer, in contrast to the clinical benefit seen in many other cancer types, includin... […]
- ASCO GU 2019: Pembrolizumab in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer on February 21, 2019 at 8:39 pm
San Francisco, CA (UroToday.com) Immune checkpoint inhibition for prostate cancer has been met with significant challenges in the immunotherapy era. Unlike the dramatic and responses seen in melanoma, ... […]
- Hypofractionated Radiotherapy for Prostate Cancer: The New ASTRO/ASCO/AUA Guideline on February 21, 2019 at 8:56 am
The American Society for Radiation Oncology (ASTRO), American Society of Clinical Oncology (ASCO), and American Urological Association (AUA) published an evidence-based clinical guideline on hypofract... […]
- ARCHES Trial “Changes Practice” for Metastatic Hormone-Sensitive Prostate Cancer on February 21, 2019 at 7:43 am
Men with metastatic hormone-sensitive prostate cancer who received enzalutamide in addition to androgen deprivation therapy (ADT) had higher response rates than those who received ADT plus placebo, ac... […]
- After the Diagnosis: Treatment Options for Kidney Cancer on February 21, 2019 at 6:48 am
This is akin to the “watchful waiting” approach used in some men who have what’s thought to be slow-growing prostate cancer, rather than treating it immediately with surgery or radiation. […]
- Foresee Pharmaceuticals Announces Successful Topline Results from Phase 3 Registration Study of LMIS 25 mg in Prostate Cancer on February 21, 2019 at 2:30 am
TAIPEI, Taiwan, February 21, 2019 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), announced today the topline results of FP-001 LMIS (Leuprolide Mesylate Injectable Suspensio... […]
- Hormone therapies for prostate cancer benefit black men more than white men on February 20, 2019 at 2:31 pm
SAN FRANCISCO — Chemotherapy-naive black men with metastatic castration-resistant prostate cancer appeared to survive longer with abiraterone acetate or enzalutamide than their white counterparts, acc... […]
- Health Check: Men with prostate cancer opt for 'active surveillance' over treatment on February 19, 2019 at 3:09 pm
PROVIDENCE, R.I. (WJAR) -- More men diagnosed with prostate cancer are choosing not to be treated. These are men who are considered at low risk for their cancer to progress. At the Miriam Hospital ... […]
via Bing News